JP2014502973A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014502973A5 JP2014502973A5 JP2013548628A JP2013548628A JP2014502973A5 JP 2014502973 A5 JP2014502973 A5 JP 2014502973A5 JP 2013548628 A JP2013548628 A JP 2013548628A JP 2013548628 A JP2013548628 A JP 2013548628A JP 2014502973 A5 JP2014502973 A5 JP 2014502973A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- toll
- receptor
- cancer
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 34
- 102000002689 Toll-like receptor Human genes 0.000 claims description 24
- 108020000411 Toll-like receptor Proteins 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 23
- 241000124008 Mammalia Species 0.000 claims description 21
- 210000001519 tissue Anatomy 0.000 claims description 9
- 229940089514 Fas agonist Drugs 0.000 claims description 8
- 108010040721 Flagellin Proteins 0.000 claims description 8
- 239000003970 toll like receptor agonist Substances 0.000 claims description 8
- 229940123384 Toll-like receptor (TLR) agonist Drugs 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 5
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 230000001394 metastastic effect Effects 0.000 claims description 4
- 208000037819 metastatic cancer Diseases 0.000 claims description 4
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 206010066476 Haematological malignancy Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 238000004820 blood count Methods 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000002648 combination therapy Methods 0.000 claims description 2
- 230000015788 innate immune response Effects 0.000 claims description 2
- 210000000265 leukocyte Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 238000009097 single-agent therapy Methods 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 30
- 102000008234 Toll-like receptor 5 Human genes 0.000 claims 3
- 108010060812 Toll-like receptor 5 Proteins 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000004719 natural immunity Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 239000000556 agonist Substances 0.000 description 11
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 FAS agonist antibody Proteins 0.000 description 2
- 206010019851 Hepatotoxicity Diseases 0.000 description 2
- 206010039438 Salmonella Infections Diseases 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 108700012920 TNF Proteins 0.000 description 2
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 2
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000007686 hepatotoxicity Effects 0.000 description 2
- 231100000304 hepatotoxicity Toxicity 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 206010039447 salmonellosis Diseases 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161431313P | 2011-01-10 | 2011-01-10 | |
| US61/431,313 | 2011-01-10 | ||
| PCT/US2012/020844 WO2012097012A1 (en) | 2011-01-10 | 2012-01-10 | Use of toll-like receptor agonist for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014502973A JP2014502973A (ja) | 2014-02-06 |
| JP2014502973A5 true JP2014502973A5 (cg-RX-API-DMAC7.html) | 2015-03-05 |
| JP6041444B2 JP6041444B2 (ja) | 2016-12-07 |
Family
ID=46507417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013548628A Expired - Fee Related JP6041444B2 (ja) | 2011-01-10 | 2012-01-10 | 癌を治療するためのＴｏｌｌ様受容体アゴニストの使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (7) | US9376473B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2663367A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6041444B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140030132A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103476458B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012205681B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013017283A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2824438A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2013002001A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO6781506A2 (cg-RX-API-DMAC7.html) |
| EA (1) | EA026524B1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL227308A (cg-RX-API-DMAC7.html) |
| MX (2) | MX361355B (cg-RX-API-DMAC7.html) |
| SG (1) | SG191830A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012097012A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| CA3050530A1 (en) | 2009-01-06 | 2010-07-15 | Galenagen, Llc | Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces |
| GB2480773B (en) | 2009-01-06 | 2013-12-11 | Curelon Llc | Compositions for the treatment of diarrhea caused by virulent E. coli infections |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
| CN103476458B (zh) * | 2011-01-10 | 2017-02-15 | 克利夫兰生物实验室公司 | Toll样受体激动剂治疗癌症的用途 |
| GB2503852B (en) | 2011-04-21 | 2018-12-12 | Curemark Llc | Compounds for the treatment of neuropsychiatric disorders |
| GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
| GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| WO2014098649A1 (en) * | 2012-12-18 | 2014-06-26 | Obschestvo S Ogranichennoy Otvetstvennostyu "Panacela Labs" | Compositions and methods using toll-like receptor 5 and toll-like receptor agonist |
| GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
| CN104258375A (zh) * | 2014-09-18 | 2015-01-07 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 辐抗肽蛋白的新用途 |
| BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
| CN108138122B (zh) | 2014-12-23 | 2021-09-21 | 4D制药研究有限公司 | 免疫调控 |
| WO2016146143A1 (en) | 2015-03-16 | 2016-09-22 | Amal Therapeutics Sa | Cell penetrating peptides and complexes comprising the same |
| PT3307288T (pt) | 2015-06-15 | 2019-10-17 | 4D Pharma Res Ltd | Composições compreendendo estirpes bacterianas |
| MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| ME03511B (me) | 2015-06-15 | 2020-04-20 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
| HRP20191949T1 (hr) | 2015-06-15 | 2020-01-24 | 4D Pharma Research Limited | Blautia stercosis i wexlerae za upotrebu u liječenju upalnih i autoimunih bolesti |
| MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
| GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| SI3209310T1 (en) | 2015-11-20 | 2018-06-29 | 4D Pharma Research Limited | Compositions containing bacterial strains |
| GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
| RS58869B1 (sr) | 2016-03-04 | 2019-08-30 | 4D Pharma Plc | Kompozicije koje sadrže blautia bakterijske sojeve za lečenje visceralne hipersenzitivnosti |
| HUE066998T2 (hu) | 2016-03-16 | 2024-09-28 | Amal Therapeutics Sa | Egy immunellenõrzõpont-modulátor és egy sejtpenetráló peptidet, kargót és TLR peptidagonistát tartalmazó komplex kombinációja gyógyászatban történõ alkalmazásra |
| TWI802545B (zh) | 2016-07-13 | 2023-05-21 | 英商４Ｄ製藥有限公司 | 包含細菌菌株之組合物 |
| WO2018055060A1 (en) | 2016-09-21 | 2018-03-29 | Amal Therapeutics Sa | Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer |
| US20180193003A1 (en) | 2016-12-07 | 2018-07-12 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
| CA3046019A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a tlr modulator |
| RU2650610C1 (ru) | 2017-02-28 | 2018-04-16 | Васильевич Иващенко Александр | Противовирусная композиция и способ ее применения |
| EP3609528A4 (en) | 2017-04-10 | 2020-12-23 | Curemark, LLC | COMPOSITIONS FOR THE TREATMENT OF ADDICTION |
| EP3630137B1 (en) | 2017-05-22 | 2023-05-17 | 4D Pharma Research Limited | Compositions comprising bacterial strains |
| TW201907931A (zh) | 2017-05-24 | 2019-03-01 | 英商4D製藥研究有限公司 | 包含細菌菌株之組合物 |
| SG11201912105PA (en) | 2017-06-14 | 2020-01-30 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
| PL3638271T3 (pl) | 2017-06-14 | 2021-03-22 | 4D Pharma Research Limited | Kompozycje zawierające szczepy bakteryjne |
| HUE059249T2 (hu) | 2017-06-14 | 2022-11-28 | 4D Pharma Res Limited | Baktériumtörzseket tartalmazó készítmények |
| CN111491654A (zh) | 2017-07-20 | 2020-08-04 | 斯波根生物技术公司 | 用于改善植物的保护、生长和生产力的生物活性多肽 |
| MD3768284T2 (ro) | 2018-03-19 | 2022-06-30 | 4D Pharma Res Ltd | Compoziţii de entrecoccus flagellin pentru utilizare în terapie |
| CN108404113A (zh) * | 2018-05-16 | 2018-08-17 | 中国人民解放军军事科学院军事医学研究院 | 用于抗辐射损伤的口服辐抗肽药物组合物 |
| CN108478782B (zh) * | 2018-05-16 | 2021-05-18 | 中国人民解放军军事科学院军事医学研究院 | 辐抗肽在促肝细胞再生中的应用 |
| US12440536B2 (en) * | 2018-05-18 | 2025-10-14 | The University Of Hong Kong | Compositions of toll-like receptor 5 (TLR5) agonist and methods of use thereof |
| CN111109198B (zh) * | 2019-03-29 | 2021-08-20 | 成都华西海圻医药科技有限公司 | 一种葡萄膜炎动物模型构建方法 |
| CN114502573A (zh) * | 2019-08-30 | 2022-05-13 | 基因组保护股份有限公司 | 提高疫苗功效的方法 |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| JP7598660B2 (ja) * | 2020-06-04 | 2024-12-12 | ザ カトリック ユニバーシティ オブ コリア インダストリー－アカデミック コーオペレイション ファウンデーション | フラジェリン由来のｔｌｒ５アゴニストを有効成分として含む抗がん剤組成物 |
| US20230226050A1 (en) | 2020-07-02 | 2023-07-20 | Viiv Healthcare Company | Method of achieving hiv viral remission using long-acting antiretroviral agents |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
| EP4242314A4 (en) * | 2020-11-09 | 2025-03-12 | CNCure Biotech, Inc. | Salmonella strain for prevention and treatment of cancer and use thereof |
| KR102543157B1 (ko) * | 2020-11-16 | 2023-06-14 | 아주대학교산학협력단 | 톨-유사 수용체 1/2 및/또는 4 활성화 펩타이드 및 이의 용도 |
| CN114592007B (zh) * | 2022-04-29 | 2023-10-27 | 昆明理工大学 | Far1基因的新用途 |
| WO2025196053A1 (en) | 2024-03-18 | 2025-09-25 | Istituto Europeo Di Oncologia S.R.L. | Flagellin-related peptides and uses thereof |
| EP4620482A1 (en) * | 2024-03-18 | 2025-09-24 | Istituto Europeo di Oncologia S.r.l. | Flagellin-related peptides and uses thereof |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3007812A (en) | 1957-02-11 | 1961-11-07 | Allied Chem | Water-repellent compositions, method of water-proofing porous surfaces therewith, and resulting water-repellent surfaces |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5399494A (en) | 1983-03-04 | 1995-03-21 | The University Of Maryland System | Vibrio cholerae strain CVD103Hgr, method of making same, and vaccines derived therefrom |
| US6130082A (en) | 1988-05-05 | 2000-10-10 | American Cyanamid Company | Recombinant flagellin vaccines |
| ES2088014T3 (es) | 1990-09-28 | 1996-08-01 | Sulzer Innotec Ag | Aguja hueca para utilizacion medica y procedimiento para la fabricacion de este tipo de agujas huecas. |
| DE69334197T2 (de) | 1992-03-02 | 2008-12-11 | Novartis Vaccines And Diagnostics S.R.L. | Helicobacter pylori Cytotoxin verwendbar in Impfstoffe und Diagnostik |
| US5693476A (en) | 1995-02-24 | 1997-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of screening for compounds capable of modulating vesicular release |
| US20020009747A1 (en) | 1997-08-25 | 2002-01-24 | Freda Diane Miller | Methods and reagents for identifying modulators of neuronal apoptosis |
| US5994409A (en) | 1997-12-09 | 1999-11-30 | U.S. Bioscience, Inc. | Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds |
| WO2001040280A2 (en) | 1999-11-29 | 2001-06-07 | Inotek Corporation | Composition and method for treating a microbial infection |
| HK1047945B (en) | 2000-01-31 | 2007-12-28 | Munin Corporation | Human cyr61 |
| US7300749B2 (en) | 2000-02-17 | 2007-11-27 | Millennium Pharmaceuticals, Inc. | Molecules of the pyrin domain protein family and uses thereof |
| AU2002216500A1 (en) | 2000-11-28 | 2002-06-11 | Genesis Research And Development Corporation Limited | Methods for modulating apoptotic cell death |
| US8703146B2 (en) | 2001-04-20 | 2014-04-22 | Institute For Systems Biology | Toll-like receptor 5 ligands and methods of use |
| ATE463505T1 (de) | 2001-04-20 | 2010-04-15 | Inst Systems Biology | Toll-ähnlichen-rezeptor-5-liganden und verwendungsverfahren |
| WO2003028659A2 (en) | 2001-10-02 | 2003-04-10 | University Of Chicago | Methods and compositions for modulating apoptosis |
| US7078165B2 (en) | 2003-03-27 | 2006-07-18 | Institut Pasteur | Method for modulating Nod1 activity, use of a MTP related molecule for modulating Nod1 activity, and therapeutic applications thereof |
| US7638485B2 (en) | 2003-12-02 | 2009-12-29 | Cleveland Biolabs, Inc. | Modulating apoptosis |
| WO2005056041A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING LATENT TGFβ |
| WO2005056054A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | METHODS OF INHIBITING APOPTOSIS USING INDUCERS OF NF-κB |
| WO2005056042A2 (en) | 2003-12-02 | 2005-06-23 | Cleveland Clinic Foundation | Methods of protecting against radiation using flagellin |
| US20050266391A1 (en) | 2004-01-15 | 2005-12-01 | Bennett Brydon L | Methods for preserving tissue |
| WO2006039701A1 (en) * | 2004-10-01 | 2006-04-13 | University Of South Florida | Flagellin-based adjuvants and vaccines |
| WO2006066214A2 (en) | 2004-12-16 | 2006-06-22 | Wake Forest University Health Sciences | Use of flagellin in the immunotherapy of yersinia pestis |
| JP5285278B2 (ja) | 2004-12-22 | 2013-09-11 | クリーブランド クリニック ファウンデイション | フラゲリン関連ポリペプチドおよびその使用 |
| EP1940419A2 (en) | 2005-09-09 | 2008-07-09 | Oregon Health and Science University | Neuroprotectants |
| US20070269406A1 (en) * | 2005-12-14 | 2007-11-22 | Ichim Thomas E | Transcatheter tumor immunoembolization |
| EP1979488A4 (en) * | 2006-01-09 | 2009-05-27 | Univ California | IMMUNOSTIMULATING COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERIC RECEPTOR, AND CYTOKIN RECEPTOR ANTONISTS FOR VACCINES AND TUMOR IMMUNOTHERAPY |
| WO2008094275A1 (en) | 2007-01-30 | 2008-08-07 | New York University | Peptides for treatment of conditions associated with nitric oxide |
| CN101778861A (zh) * | 2007-06-15 | 2010-07-14 | Immurx公司 | Tlr激动剂和/或1型干扰素减轻tnf-r激动剂治疗方案的毒性的用途 |
| WO2009018500A1 (en) | 2007-07-31 | 2009-02-05 | The Johns Hopkins University | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| DK2224954T3 (en) * | 2007-11-07 | 2014-03-03 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| WO2009102818A1 (en) | 2008-02-11 | 2009-08-20 | Cleveland Biolabs, Inc. | Method for reducing the effects of chemotheraphy using flagellin related polypeptides |
| ES2412237T3 (es) | 2008-08-01 | 2013-07-10 | Cleveland Biolabs, Inc. | Métodos para tratar lesiones por reperfusión |
| EA201101650A1 (ru) | 2009-05-21 | 2012-07-30 | Астразенека Аб | Новые производные пиримидина и их применение в лечении злокачественных новообразований и последующих заболеваний |
| EA026401B1 (ru) | 2009-09-02 | 2017-04-28 | Новартис Аг | Иммуногенные композиции, содержащие модуляторы активности tlr |
| EP2486134B1 (en) | 2009-10-06 | 2014-01-08 | Panacela Labs, Inc. | Use of toll-like receptor and agonist for treating cancer |
| CN103476458B (zh) * | 2011-01-10 | 2017-02-15 | 克利夫兰生物实验室公司 | Toll样受体激动剂治疗癌症的用途 |
-
2012
- 2012-01-10 CN CN201280009451.0A patent/CN103476458B/zh not_active Expired - Fee Related
- 2012-01-10 BR BR112013017283A patent/BR112013017283A2/pt active Search and Examination
- 2012-01-10 AU AU2012205681A patent/AU2012205681B2/en not_active Ceased
- 2012-01-10 US US13/979,104 patent/US9376473B2/en not_active Expired - Fee Related
- 2012-01-10 JP JP2013548628A patent/JP6041444B2/ja not_active Expired - Fee Related
- 2012-01-10 SG SG2013051396A patent/SG191830A1/en unknown
- 2012-01-10 EP EP12734417.4A patent/EP2663367A4/en not_active Withdrawn
- 2012-01-10 WO PCT/US2012/020844 patent/WO2012097012A1/en not_active Ceased
- 2012-01-10 MX MX2013007967A patent/MX361355B/es active IP Right Grant
- 2012-01-10 EA EA201390843A patent/EA026524B1/ru not_active IP Right Cessation
- 2012-01-10 KR KR1020137021035A patent/KR20140030132A/ko not_active Withdrawn
- 2012-01-10 CA CA2824438A patent/CA2824438A1/en not_active Abandoned
-
2013
- 2013-07-03 IL IL227308A patent/IL227308A/en active IP Right Grant
- 2013-07-08 CL CL2013002001A patent/CL2013002001A1/es unknown
- 2013-07-08 MX MX2018014998A patent/MX2018014998A/es unknown
- 2013-07-29 CO CO13178553A patent/CO6781506A2/es not_active Application Discontinuation
-
2015
- 2015-11-23 US US14/949,441 patent/US20160206690A1/en not_active Abandoned
-
2016
- 2016-08-19 US US15/241,757 patent/US20170065692A1/en not_active Abandoned
-
2017
- 2017-06-23 US US15/631,427 patent/US10034926B2/en active Active
-
2018
- 2018-06-21 US US16/014,419 patent/US10265390B2/en active Active
-
2019
- 2019-02-19 US US16/279,457 patent/US10780152B2/en not_active Expired - Fee Related
-
2020
- 2020-07-21 US US16/934,556 patent/US11628201B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014502973A5 (cg-RX-API-DMAC7.html) | ||
| PH12017500484A1 (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers | |
| PH12018500189A1 (en) | Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers | |
| PH12018500864A1 (en) | Peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers | |
| PH12017501651B1 (en) | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers | |
| CR20200555A (es) | PÉPTIDOS Y COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE MAMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0135) | |
| CR20200596A (es) | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA LA LEUCEMIA LINFOCÍTICA CRÓNICA (LLC) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0295) | |
| WO2012097313A3 (en) | Therapeutic antibodies against ror-1 protein and methods for use of same | |
| BR112012025567A2 (pt) | peptídeos de cdca5 e vacinas que incluem os mesmos | |
| BR112014001363A2 (pt) | peptídeos mphosph1 e vacinas incluindo os mesmos | |
| BR112013031056A2 (pt) | peptídeos de sema5b e vacinas incluindo os mesmos | |
| MX2020011791A (es) | Nuevos peptidos y nueva combinacion de peptidos para el uso en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cancer. | |
| BR112012022641A2 (pt) | peptídeos hjurp e vacinas que incluem os mesmos | |
| MX2012011385A (es) | Peptidos ect2 y vacunas que los incluyen. | |
| PH12018500665A1 (en) | Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers | |
| SG10201408245WA (en) | Tmem22 peptides and vaccines including the same | |
| Sossa-Rojas | Estudio del potencial oncolítico del aislamiento rotaviral humano Wt1-5 en adenocarcinoma gástrico | |
| WO2013040547A3 (en) | Compounds and methods of immunization with tumor antigens | |
| PH12012501935A1 (en) | Ect2 peptides and vaccines including the same | |
| NZ770913A (en) | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |